Apretude (cabotegravir) is a prescription drug used to help prevent HIV. It comes as a liquid suspension that a healthcare professional injects into your muscle. Apretude is a long-acting drug that’s ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The application is supported by data from the phase 2b/3 HPTN 083 and HPTN 084 trials, which evaluated the efficacy and safety of Apretude for HIV PrEP. The Food and Drug Administration (FDA) has ...
GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP) ...
In a move to increase access to HIV-prevention treatment, the U.S. Food and Drug Administration on Monday approved the use of Apretude – the first injectable pre-exposure prophylaxis treatment aimed ...
With Gilead Sciences sprinting to a likely approval next year for its long-acting pre-exposure prophylaxis (PrEP) drug for HIV, the California company has a chance to one-up GSK. While the British ...
The Food and Drug Administration has approved the first long-acting injectable medication for use as pre-exposure prevention, or PrEP, against HIV, the agency announced Monday. Subscribe to read this ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
The full CMI on the next page has more details. If you are worried about using this medicine, speak to your doctor or pharmacist. This medicine is new or being used differently. Please report side ...
The Food and Drug Administration on Monday approved the world’s first injectable medication to reduce the risk of sexually transmitted HIV. Previously, the only PrEP (pre-exposure prophylaxis) ...
GlaxoSmithKline' majority-owned HIV unit ViiV has scored a key FDA approval, getting approval for its long-acting drug cabotegravir as the first injectable for pre-exposure prophylaxis (PrEP) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results